Compare Ascendis Pharma A/S (ASND) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs General Dynamics Corporation — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while General Dynamics Corporation trades at $372.14 (market cap $101.43B). The key difference: General Dynamics Corporation is far larger — about 5.7× Ascendis Pharma A/S's market cap, and General Dynamics Corporation pays a 1.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GD | |
|---|---|---|
Market Cap | $17.74B | $101.43B |
Sector | Health | Industrials |
52-Week High | $277.18 | $376.88 |
52-Week Low | $163.32 | $297.05 |
Enterprise Value | $18.11B | $107.61B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
General Dynamics (GD) trades at $375.06, up 0.12% today, near its 52-week high with strong technical momentum. The stock shows robust fundamentals, including consistent earnings beats, revenue growth to $52.55B in 2025, and healthy margins. Analyst sentiment is bullish, with a consensus price target of $395.83, supported by a backlog surge to $130.8B in Q1 2026 (Seeking Alpha, 2026-07-02).
Outlook remains positive due to defense spending tailwinds and submarine contract wins, but risks include execution delays and valuation concerns. The stock offers growth potential with a 5.6% upside to consensus target, though high RSI levels suggest near-term overbought conditions. Investors should weigh strong cash flow and dividend stability against geopolitical and supply chain uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
